# Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

> **NCT07151872** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- CLDN18.2-positive Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** QLS31905 for Injection
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Cisplatin for Injection
- **DRUG:** QL2107 Injection
- **DRUG:** Oxaliplatin Injection
- **DRUG:** Capecitabine Tablets

## Key facts

- **NCT ID:** NCT07151872
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151872, "Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07151872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*